Pediatric Asthma
No Results
No Results
processing….
Asthma, which occurs in adult and pediatric patients, is a chronic inflammatory disorder of the airways characterized by an obstruction of airflow. Among children and adolescents aged 5-17 years, asthma accounts for a loss of 10 million school days annually and costs caretakers $726.1 million per year because of work absence. [1]
History
The clinician should establish whether the patient has any of the following symptoms:
Wheezing: A musical, high-pitched whistling sound produced by airflow turbulence is one of the most common symptoms of asthma. The wheezing is usually during exhalation.
Cough: Usually, the cough is nonproductive and nonparoxysmal; coughing may be present with wheezing
Cough at night or with exercise: Coughing may be the only symptom of asthma, especially in cases of exercise-induced or nocturnal asthma; children with nocturnal asthma tend to cough after midnight, during the early hours of morning
Shortness of breath
Chest tightness: A history of tightness or pain in the chest may be present with or without other symptoms of asthma, especially in exercise-induced or nocturnal asthma
Sputum production
In an acute episode of asthma, symptoms vary according to the episode’s severity. Infants and young children suffering a severe episode display the following characteristics:
Breathless during rest
Not interested in feeding
Sit upright
Talk in words (not sentences)
Usually agitated
With imminent respiratory arrest, the child displays the aforementioned symptoms and is also drowsy and confused. However, adolescents may not have these symptoms until they are in frank respiratory failure.
Physical examination
Findings during a severe episode include the following:
Respiratory rate is often greater than 30 breaths per minute
Accessory muscles of respiration are usually used
Suprasternal retractions are commonly present
The heart rate is greater than 120 beats per minute
Loud biphasic (expiratory and inspiratory) wheezing can be heard
Pulsus paradoxus is often present (20-40 mm Hg)
Oxyhemoglobin saturation with room air is less than 91%
Findings in status asthmaticus with imminent respiratory arrest include the following:
Paradoxical thoracoabdominal movement occurs
Wheezing may be absent (in patients with the most severe airway obstruction)
Severe hypoxemia may manifest as bradycardia
Pulsus paradoxus may disappear: This finding suggests respiratory muscle fatigue
See Clinical Presentation for more detail.
Tests used in the diagnosis of asthma include the following:
Pulmonary function tests: Spirometry and plethysmography
Exercise challenge: Involves baseline spirometry followed by exercise on a treadmill or bicycle to a heart rate greater than 60% of the predicted maximum, with monitoring of the electrocardiogram and oxyhemoglobin saturation
Fraction of exhaled nitric oxide (FeNO) testing: Noninvasive marker of airway inflammation
Radiography: Reveals hyperinflation and increased bronchial markings; radiography may also show evidence of parenchymal disease, atelectasis, pneumonia, congenital anomaly, or a foreign body
Allergy testing: Can identify allergic factors that may significantly contribute to asthma
Histologic evaluation of the airways: Typically reveal infiltration with inflammatory cells, narrowing of airway lumina, bronchial and bronchiolar epithelial denudation, and mucus plugs
See Workup for more detail.
Guidelines from the National Asthma Education and Prevention Program emphasize the following components of asthma care [2] :
Assessment and monitoring: In order to assess asthma control and adjust therapy, impairment and risk must be assessed; because asthma varies over time, follow-up every 2-6 weeks is initially necessary (when gaining control of the disease), and then every 1-6 months thereafter
Education: Self-management education should focus on teaching patients the importance of recognizing their own level of control and signs of progressively worsening asthma symptoms; educational strategies should also focus on environmental control and avoidance strategies, as well as on medication use and adherence (eg, correct inhaler techniques and use of other devices)
Control of environmental factors and comorbid conditions
Pharmacologic treatment
Pharmacologic treatment
Pharmacologic asthma management includes the use of agents for control and agents for relief. Control agents include the following:
Inhaled corticosteroids
Inhaled cromolyn or nedocromil
Long-acting bronchodilators
Theophylline
Leukotriene modifiers
Anti-immunoglobulin E (IgE) antibodies (omalizumab)
Interleukin inhibitors (eg, mepolizumab, benralizumab, dupilumab)
Relief medications include the following:
Short-acting bronchodilators
Systemic corticosteroids
Ipratropium
See Treatment and Medication for more detail.
Asthma is a chronic inflammatory disorder of the airways characterized by an obstruction of airflow, which may be completely or partially reversed with or without specific therapy. Airway inflammation is the result of interactions between various cells, cellular elements, and cytokines. In susceptible individuals, airway inflammation may cause recurrent or persistent bronchospasm, which causes symptoms that include wheezing, breathlessness, chest tightness, and cough, particularly at night (early morning hours) or after exercise.
Airway inflammation is associated with airway hyperreactivity or bronchial hyperresponsiveness (BHR), which is defined as the inherent tendency of the airways to narrow in response to various stimuli (eg, environmental allergens and irritants). [3]
Asthma affects an estimated 300 million individuals worldwide (see Epidemiology). The prevalence of asthma is increasing, especially in children. Annually, the World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are lost and 250,000 asthma deaths are reported worldwide. [4] Approximately 500,000 annual hospitalizations (34.6% in individuals aged 18 y or younger) are due to asthma. In the United States, asthma prevalence, having increased from 1980 to 1996, showed a plateau at 9.1% of children (6.7 million) in 2007. [5]
The cost of illness related to asthma is around $6.2 billion. Each year, an estimated 1.81 million people (47.8% in individuals aged 18 y or younger) require treatment in the emergency department. Among children and adolescents aged 5-17 years, asthma accounts for a loss of 10 million school days and costs caretakers $726.1 million because of work absence. [1]
Guidelines from the National Asthma Education and Prevention Program provide recommendations on the diagnosis and treatment of pediatric asthma (see Clinical Presentation, Workup, and Treatment and Management).
Interactions between environmental and genetic factors result in airway inflammation, which limits airflow and leads to functional and structural changes in the airways in the form of bronchospasm, mucosal edema, and mucus plugs.
Airway obstruction causes increased resistance to airflow and decreased expiratory flow rates. These changes lead to a decreased ability to expel air and may result in hyperinflation. The resulting overdistention helps maintain airway patency, thereby improving expiratory flow; however, it also alters pulmonary mechanics and increases the work of breathing.
Hyperinflation compensates for the airflow obstruction, but this compensation is limited when the tidal volume approaches the volume of the pulmonary dead space; the result is alveolar hypoventilation. Uneven changes in airflow resistance, the resulting uneven distribution of air, and alterations in circulation from increased intra-alveolar pressure due to hyperinflation all lead to ventilation-perfusion mismatch.
Vasoconstriction due to alveolar hypoxia also contributes to this mismatch. Vasoconstriction is also considered an adaptive response to ventilation/perfusion mismatch.
In the early stages, when ventilation-perfusion mismatch results in hypoxia, hypercarbia is prevented by the ready diffusion of carbon dioxide across alveolar capillary membranes. Thus, patients with asthma who are in the early stages of an acute episode have hypoxemia in the absence of carbon dioxide retention. Hyperventilation triggered by the hypoxic drive also causes a decrease in PaCO2. An increase in alveolar ventilation in the early stages of an acute exacerbation prevents hypercarbia.
With worsening obstruction and increasing ventilation-perfusion mismatch, carbon dioxide retention occurs. In the early stages of an acute episode, respiratory alkalosis results from hyperventilation. Later, the increased work of breathing, increased oxygen consumption, and increased cardiac output result in metabolic acidosis. Respiratory failure leads to respiratory acidosis. Fatigue is also a potential contributor to respiratory acidosis.
Chronic inflammation of the airways is associated with increased BHR, which leads to bronchospasm and typical symptoms of wheezing, shortness of breath, and coughing after exposure to allergens, environmental irritants, viruses, cold air, or exercise. In some patients with chronic asthma, airflow limitation may be only partially reversible because of airway remodeling (hypertrophy and hyperplasia of smooth muscle, angiogenesis, and subepithelial fibrosis) that occurs with chronic untreated disease.
New insights in the pathogenesis of asthma suggest that lymphocytes play a role. Airway inflammation in asthma may represent a loss of normal balance between two “opposing” populations of T helper (Th) lymphocytes. Two types of Th lymphocytes have been characterized: Th1 and Th2. Th1 cells produce interleukin (IL)-2 and interferon-α (IFN-α), which are critical in cellular defense mechanisms in response to infection. Th2, in contrast, generates a family of cytokines (interleukin-4 [IL-4], IL-5, IL-6, IL-9, and IL-13) that can mediate allergic inflammation.
The current “hygiene hypothesis” of asthma illustrates how this cytokine imbalance may explain some of the dramatic increases in asthma prevalence in Westernized countries. [6] This hypothesis is based on the concept that the immune system of the newborn is skewed toward Th2 cytokine generation (mediators of allergic inflammation). Over time, environmental stimuli such as infections activate Th1 responses and bring the Th1/Th2 relationship to an appropriate balance.
Evidence suggests that the prevalence of asthma is reduced in children who experience the following events:
Certain infections (Mycobacterium tuberculosis, measles, or hepatitis A)
Rural living
Exposure to other children (eg, presence of older siblings and early enrollment in childcare
Less frequent use of antibiotics, including in the first week of life [7]
Early introduction of fish in the diet [7]
Furthermore, the absence of these lifestyle events is associated with the persistence of a Th2 cytokine pattern.
Under these conditions, the genetic background of the child, with a cytokine imbalance toward Th2, sets the stage to promote the production of immunoglobulin E (IgE) antibody to key environmental antigens (eg, dust mites, cockroaches, Alternaria, and possibly cats). Therefore, a gene-by-environment interaction occurs in which the susceptible host is exposed to environmental factors that are capable of generating IgE, and sensitization occurs.
A reciprocal interaction is apparent between the two subpopulations, in which Th1 cytokines can inhibit Th2 generation and vice versa. Allergic inflammation may be the result of an excessive expression of Th2 cytokines. Alternatively, recent studies have suggested the possibility that the loss of normal immune balance arises from a cytokine dysregulation in which Th1 activity in asthma is diminished. [8]
Results of two recently reported cross sectional studies of children growing up on farms in Central Europe who were exposed to greater variety of environmental microorganisms showed an inverse relationship between microbial exposure and the probability of asthma. [9]
Some studies highlight the importance of genotypes in contributing to asthma susceptibility and allergic sensitization, as well as response to specific asthma treatments. [10, 11, 12, 13]
Through the use of cluster analysis, the Severe Asthma Research Program of the National Heart, Lung, and Blood Institute identified 5 phenotypes of asthma. [14] Cluster 1 patients have early-onset atopic asthma with normal lung function treated with two or fewer controller medications and minimal health care utilization. Cluster 2 patients have early-onset atopic asthma and preserved lung function but increased medication requirements (29% on three or more medications) and health care utilization.
Cluster 3 comprises mostly older obese women with late-onset nonatopic asthma, moderate reductions in pulmonary function, and frequent oral corticosteroid use to manage exacerbations. Cluster 4 and cluster 5 patients have severe airflow obstruction with bronchodilator responsiveness but differ in to their ability to attain normal lung function, age of asthma onset, atopic status, and use of oral corticosteroids. [14]
A recently reported meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations identified 5 susceptibility loci. Four were on previously reported loci on 17q21 and a new asthma susceptibility locus at PYHIN1, which is specific to the African American population. [15]
An Australian study identified 2 new loci with genome-wide significant association with asthma risk: rs4129267 in IL6R and rs7130588 on band 11q13.5. The IL6R association supports the hypothesis that cytokine dysregulation affects asthma risk, hence a specific antagonist to IL6R may help. The results for the 11q13.5 locus suggest its association with allergic sensitization and subsequent development of asthma. [16]
A study that examined whether the lipid profile is associated with concurrent asthma concluded that the blood lipid profile is associated with asthma, airway obstruction, bronchial responsiveness, and aeroallergen sensitization in 7-year-old children. Caution must be applied before saying that asthma might be a systemic disorder. First, we don’t know if the children with the elevated LDL levels were more likely exposed to higher doses of inhaled, or systemic corticosteroids. The authors did find that those with worse lung function had higher LDL levels. However, it could also be that those children exercised less, a potential cause of obesity and abnormal lipid levels. The BMI was also not reported. [17, 18]
A 2012 study reported a significant association between lung function deficit and bronchial responsiveness in the neonatal period with development of asthma by age seven years. [19]
Lemanske et al reported that wheezing illnesses caused by rhinovirus infection during infancy were the strongest predictor of wheezing in the third year of life. [20]
In a study of preschool children with asthma, Guilbert et al found that 2 years of inhaled corticosteroid therapy did not change the asthma symptoms or lung function during a third, treatment-free year. This suggests that no disease-modifying effect of inhaled corticosteroids is present after the treatment is discontinued. [21]
In a study of children in the Cincinnati area, Reponen et al found that a high Environmental Relative Moldiness Index (ERMI) [22] at age 1 year made asthma at age 7 years more likely. The ERMI did not predict specific mold allergies at age 7 years. Air conditioning made asthma less likely. An elevated ERMI at age 7 years had no correlation with current asthma. Seeing or smelling mold in a home inspection at age 1 year did not correlate with the ERMI or with the development of asthma. They also found that black race, having a parent with asthma, and house dust allergy was predictive of a greater likelihood of asthma. [23]
A recent study from Australia reported that obesity is a determinant of asthma control independent of inflammation, lung function, and airway hyperresponsiveness. [24] A similar association between increased risk of worse asthma control and obesity was reported in a recent retrospective study of 32,321 children aged 5-17 years. [25]
A significant inverse relationship between serum vitamin D levels and patient IgE levels, steroid requirements, and in vitro responsiveness to corticosteroids in children has been reported. [26]
Parental cigarette smoking has been shown to increase the likelihood of asthma. This is more true for maternal smoking, though the authors of one study did not correct for primary caretakers. The more cigarettes the mother smoked, the greater the risk of asthma. [27]
A randomized clinical trial by Sheehan et al evaluated the association in children between frequent acetaminophen use and asthma-related complications. The study found that among young children with mild persistent asthma, as-needed use of acetaminophen was not shown to be associated with a higher incidence of asthma exacerbations or worse asthma control than was as-needed use of ibuprofen. [28, 29]
In most cases of asthma in children, multiple triggers or precipitants are recognized, and the patterns of reactivity may change with age. Treatment can also change the pattern. Wheeze is common with respiratory syncytial virus (RSV) bronchiolitis and recurrent wheeze may persist up to 3-5 years. However, RSV is unlikely the sole explanation for the development of atopic asthma later in life. On the other hand, infection with human rhinovirus that requires hospitalization has been associated with future development of asthma (age 6 y).
Most commonly, these are viral infections. In some patients, fungi (eg, allergic bronchopulmonary aspergillosis), bacteria (eg, Mycoplasma, pertussis), or parasites may be responsible. Most infants and young children who continue to have a persistent wheeze and asthma have high immunoglobulin E (IgE) production and eosinophilic immune responses (in the airways and in circulation) at the time of the first viral upper respiratory tract infection (URTI). They also have early IgE-mediated responses to local aeroallergens.
In patients with asthma, 2 types of bronchoconstrictor responses to allergens are recognized: early and late. Early asthmatic responses occur via IgE-induced mediator release from mast cells within minutes of exposure and last for 20-30 minutes.
Late asthmatic responses occur 4-12 hours after antigen exposure and result in more severe symptoms that can last for hours and contribute to the duration and severity of the disease. Inflammatory cell infiltration and inflammatory mediators play a role in the late asthmatic response. Allergens can be foods, household inhalants (eg, animal allergens, molds, fungi, roach allergens, dust mites), or seasonal outdoor allergens (eg, mold spores, pollens, grass, trees).
Tobacco smoke, cold air, chemicals, perfumes, paint odors, hair sprays, air pollutants, and ozone can initiate BHR by inducing inflammation.
Asthma attacks can be related to changes in atmospheric temperature, barometric pressure, and the quality of air (eg, humidity, allergen and irritant content). In some individuals, emotional upsets clearly aggravate asthma.
Exercise can trigger an early asthmatic response. Mechanisms underlying exercise-induced asthmatic response remain somewhat uncertain. Heat and water loss from the airways can increase the osmolarity of the fluid lining the airways and result in mediator release. Cooling of the airways results in congestion and dilatation of bronchial vessels. During the rewarming phase after exercise, the changes are magnified because the ambient air breathed during recovery is warm rather than cool.
The presence of acid in the distal esophagus, mediated via vagal or other neural reflexes, can significantly increase airway resistance and airway reactivity. Inflammatory conditions of the upper airways (eg, allergic rhinitis, sinusitis, or chronic and persistent infections) must be treated before asthmatic symptoms can be completely controlled.
Multiple factors have been proposed to explain nocturnal asthma. Circadian variation in lung function and inflammatory mediator release in the circulation and airways (including parenchyma) have been demonstrated. Other factors, such as allergen exposure and posture-related irritation of airways (eg, gastroesophageal reflux, sinusitis), can also play a role. In some cases, abnormalities in CNS control of the respiratory drive may be present, particularly in patients with a defective hypoxic drive and obstructive sleep apnea.
Children exposed to higher maternal stress during the pre- and postnatal period were reported to be at higher risk for wheeze. This was only true in non-atopic mothers. [30]
A 2012 Danish study reported an association between maternal obesity (BMI ≥35 and gestational weight gain ≥25 kg) during pregnancy with increased risk of asthma and wheezing in the offspring. [31]
Results of a prospective birth cohort study of 568 pregnant women and their offspring showed that postnatal bisphenol A (BPA) exposure in the first years of a child’s life is associated with significantly increased risk for wheeze and asthma. Feeding bottles, sippy cups, or other containers designed for infants may contain it. The study also found, however, that fetal exposure to BPA during the third trimester of pregnancy was inversely associated with risk for wheeze in offspring at age 5 years. [32, 33]
Approximately 34.1 million people in the United States have been diagnosed with asthma in their lifetime. According to the most recent US Centers for Disease Control and Prevention (CDC) Asthma Surveillance Survey, the prevalence of current asthma during 2001-2003 prevalence is estimated at 6.7% in adults and 8.5% in children, and the burden of asthma increased more than 75% from 1980-1999. [34, 35]
Asthma accounts for more school absences and more hospitalizations than any other chronic illness. In most children’s hospitals in the United States, it is the most common diagnosis at admission.
Worldwide, 130 million people have asthma. The prevalence is 8-10 times higher in developed countries (eg, United States, Great Britain, Australia, New Zealand) than in the developing countries. In developed countries, the prevalence is higher in low-income groups in urban areas and inner cities than in other groups.
A long-term study of a birth cohort on the Isle of Wight showed that maternal asthma and eczema were associated with asthma and eczema in their daughters, but not in their sons. Similarly, paternal asthma and eczema were associated with asthma and eczema in their sons, but not in their daughters. [36]
The prevalence of asthma is higher in minority groups (eg, blacks, Hispanics) than in other groups; however, findings from one study suggest that much of the recent increase in the prevalence is attributed to asthma in white children. Approximately 5-8% of all black children have asthma at some time. The prevalence in Hispanic children is reported to be as high as 15%. In blacks, the death rate is consistently higher than in whites.
Before puberty, the prevalence of asthma is 3 times higher in boys than in girls. During adolescence, the prevalence is equal among males and females. Adult-onset asthma is more common in women than in men.
In most children, asthma develops before age 5 years, and, in more than half, asthma develops before age 3 years.
Among infants, 20% have wheezing with only upper respiratory tract infections (URTIs), and 60% no longer have wheezing by age 6 years. As Martinez et al have pointed out, however, many of these children are “transient wheezers” whose symptoms subside during the preschool or early school years. [37, 38] They tend to have no allergies, although their lung function is often abnormal. These findings have led to the idea that they have small lungs.
Children in whom wheezing begins early in conjunction with allergies are more likely to have wheezing when they are aged 6-11 years. Similarly, children in whom wheezing begins after age 6 years often have allergies, and the wheezing is more likely to continue when they are aged 11 years. [20]
Of infants who wheeze with URTIs, 60% are asymptomatic by age 6 years. However, children who have asthma (recurrent symptoms continuing at age 6 y) have airway reactivity later in childhood. Some findings suggest a poor prognosis if asthma develops in children younger than 3 years, unless it occurs solely in association with viral infections.
Individuals who have asthma during childhood have significantly lower forced expiratory volume in 1 second (FEV1), higher airway reactivity, and more persistent bronchospastic symptoms than those with infection-associated wheezing.
Children with mild asthma who are asymptomatic between attacks are likely to improve and be symptom-free later in life.
Children with asthma appear to have less severe symptoms as they enter adolescence, but half of these children continue to have asthma. Asthma has a tendency to remit during puberty, with a somewhat earlier remission in girls. However, compared with men, women have more BHR.
In a prospective study of 484 Australian children, Tai and colleagues found that having severe asthma in childhood was associated with an almost 12-fold increased risk of having asthma at age 50. [39, 40] At age 50, remission of asthma had occurred in 64% of subjects with mild wheezy bronchitis/wheezy bronchitis at baseline, compared with 47% of those with asthma at baseline and 15% of those with severe asthma. In a multivariate analysis, factors that significantly predicted asthma at age 50 were severe childhood asthma (odds ratio [OR] 11.9), childhood hay fever (OR 2.0, and female sex (OR 2.0). [39, 40]
Globally, morbidity and mortality associated with asthma have increased over the last 2 decades. This increase is attributed to increasing urbanization. Despite advancements in the understanding of asthma and the development of new therapeutic strategies, the morbidity and mortality rates due to asthma definitely increased from 1980-1995.
In the United States, the mortality rate due to asthma has increased in all age, race, and sex strata. In the United States, the mortality rate due to asthma is more than 17 deaths per 1 million population (ie, 5000 deaths per year).
From 1975-1993, the number of deaths nearly doubled in people aged 5-14 years. In the northeastern and midwestern United States, the highest mortality rate has been among persons aged 5-34 years. According to the most recent report from the CDC and the National Center for Health Statistics, 187 children aged 0-17 years died from asthma, or 0.3 deaths per 100,000 children compared with 1.9 deaths per 100,000 adults aged 18 or older in the year 2002. [34]
Non-Hispanic blacks were the most likely to die from asthma and had an asthma death rate more than 200% higher than non-Hispanic whites and 160% higher than Hispanics.
Patient and parent education should include instructions on how to use medications and devices (eg, spacers, nebulizers, metered-dose inhalers [MDIs]). The patient’s MDI technique should be assessed on every visit. Discuss the management plan, which includes instructions about the use of medications, precautions with drug and/or device usage, monitoring symptoms and their severity (peak flow meter reading), and identifying potential adverse effects and necessary actions.
Write and discuss in detail a rescue plan for an acute episode. This plan should include instructions for identifying signs of an acute attack, using rescue medications, monitoring, and contacting the asthma care team. Parents should understand that asthma is a chronic disorder with acute exacerbations; hence, continuity of management with active participation by the patient and/or parents and interaction with asthma care medical personnel is important. Emphasize the importance of adherence to treatment.
Incorporate the concept of expecting full control of symptoms, including nocturnal and exercise-induced symptoms, in the management plans and goals (for all but the most severely affected patients). Avoid unnecessary restrictions in the lifestyle of the child or family. Expect the child to participate in recreational activities and sports and to attend school as usual.
A systematic review by Coffman and colleagues suggested a benefit school-based asthma education. Their review included 25 studies in children aged 4-17 years. [41] In most of those studies, compared with usual care, school-based asthma education improved knowledge of asthma (7 of 10 studies), self-efficacy (6 of 8 studies), and self-management behaviors (7 of 8 studies). Fewer studies reported favorable effects on quality of life (4 of 8 studies), days of symptoms (5 of 11 studies), nights with symptoms (2 of 4 studies), and school absences (5 of 17 studies). [41]
For patient education information, see the Asthma Center, as well as Asthma, Asthma FAQs, Understanding Asthma Medications, Asthma in Children, and Asthma in School Children: Educational Slides.
National Health Interview Survey, National Center for Health Statistics. CDC. Available at http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ashtma03-05/asthma03-05.htm.
[Guideline] Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov. 120(5 Suppl):S94-138. [Medline].
National Heart, Lung, and Blood Institute. Global Initiative for Asthma. National Institute for Health Publication. 1995. 95-3659.
Global strategy for asthma management and prevention. Global initiative for asthma (GINA) 2006. Available at http://ginasthma.org.
Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980-2007. Pediatrics. 2009 Mar. 123 Suppl 3:S131-45. [Medline].
Anderson WJ, Watson L. Asthma and the hygiene hypothesis. N Engl J Med. 2001 May 24. 344(21):1643-4. [Medline].
Goksör E, Alm B, Thengilsdottir H, Pettersson R, Aberg N, Wennergren G. Preschool wheeze – impact of early fish introduction and neonatal antibiotics. Acta Paediatr. 2011 Dec. 100(12):1561-6. [Medline].
Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000 May. 161(5):1720-45. [Medline].
Ege MJ, Mayer M, Normand AC, Genuneit J,et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med. 2011 Feb 24. 364(8):701-9. [Medline].
Zucker, M. Asthma phenotype, genotype may guide future therapies. http://www.pulmonaryreviews.com [serial online]. June 2003. 8:[Full Text].
Drazen JM, Yandava CN, Dubé L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999 Jun. 22(2):168-70. [Medline].
Thompson EE, Pan L, Ostrovnaya I, Weiss LA, Gern JE, Lemanske RF Jr, et al. Integrin beta 3 genotype influences asthma and allergy phenotypes in the first 6 years of life. J Allergy Clin Immunol. 2007 Jun. 119(6):1423-9. [Medline].
Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006 Mar 1. 173(5):519-26. [Medline]. [Full Text].
Moore WC, Meyers DA, Wenzel SE, Teague WG, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010 Feb 15. 181(4):315-23. [Medline]. [Full Text].
Torgerson DG, Ampleford EJ, Chiu GY, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet. 2011 Jul 31. 43(9):887-92. [Medline].
Ferreira MA, Matheson MC, Duffy DL, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet. 2011 Sep 10. 378(9795):1006-14. [Medline].
Vinding RK, Stokholm J, Chawes BL, Bisgaard H. Blood lipid levels associate with childhood asthma, airway obstruction, bronchial hyperresponsiveness, and aeroallergen sensitization. J Allergy Clin Immunol. 2015 Jul 3. [Medline].
Boggs W. Blood Lipid Profile Tied to Childhood Asthma and Bronchial Responsiveness. Reuters Health Information. Available at http://www.medscape.com/viewarticle/848232. July 20, 2015; Accessed: September 3, 2015.
Bisgaard H, Jensen SM, Bønnelykke K. Interaction between Asthma and Lung Function Growth in Early Life. Am J Respir Crit Care Med. 2012 Jun 1. 185(11):1183-9. [Medline].
Lemanske RF Jr, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. J Allergy Clin Immunol. 2005 Sep. 116(3):571-7. [Medline].
Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006 May 11. 354(19):1985-97. [Medline].
Vesper S, McKinstry C, Haugland R, et al. Development of an Environmental Relative Moldiness index for US homes. J Occup Environ Med. 2007 Aug. 49(8):829-33. [Medline].
Reponen T, Vesper S, Levin L, et al. High environmental relative moldiness index during infancy as a predictor of asthma at 7 years of age. Ann Allergy Asthma Immunol. 2011 Aug. 107(2):120-6. [Medline].
Farah CS, Kermode JA, Downie SR, et al. Obesity is a determinant of asthma control independent of inflammation and lung mechanics. Chest. 2011 Sep. 140(3):659-66. [Medline].
Quinto KB, Zuraw BL, Poon KY, Chen W, Schatz M, Christiansen SC. The association of obesity and asthma severity and control in children. J Allergy Clin Immunol. 2011 Nov. 128(5):964-9. [Medline].
Goleva E, Searing DA, Jackson LP, Richers BN, Leung DY. Steroid requirements and immune associations with vitamin D are stronger in children than adults with asthma. J Allergy Clin Immunol. 2012 Feb 11. [Medline].
Mitchell EA, Beasley R, Keil U, Montefort S, Odhiambo J. The association between tobacco and the risk of asthma, rhinoconjunctivitis and eczema in children and adolescents: analyses from Phase Three of the ISAAC programme. Thorax. 2012 Jun 12. [Medline].
Sheehan WJ, Mauger DT, Paul IM, et al. Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma. N Engl J Med. 2016 Aug 18. 375 (7):619-30. [Medline].
Barclay L. Acetaminophen vs Ibuprofen Does Not Worsen Childhood Asthma. Medscape Medical News. Available at http://www.medscape.com/viewarticle/867592. August 17, 2016; Accessed: August 19, 2016.
Mathilda Chiu YH, Coull BA, Cohen S, Wooley A, Wright RJ. Prenatal and postnatal maternal stress and wheeze in urban children: effect of maternal sensitization. Am J Respir Crit Care Med. 2012 Jul 15. 186(2):147-54. [Medline]. [Full Text].
Harpsøe MC, Basit S, Bager P, Wohlfahrt J, Benn CS, Nøhr EA, et al. Maternal obesity, gestational weight gain, and risk of asthma and atopic disease in offspring: A study within the Danish National Birth Cohort. J Allergy Clin Immunol. 2012 Nov 1. [Medline].
Donohue KM, Miller RL, Perzanowski MS, Just AC, Hoepner LA, Arunajadai S, et al. Prenatal and postnatal bisphenol A exposure and asthma development among inner-city children. J Allergy Clin Immunol. 2013 Mar. 131(3):736-742.e6. [Medline].
Barclay L. BPA Exposure Linked to Childhood Asthma Risk. Available at http://www.medscape.com/viewarticle/780110. Accessed: March 12, 2013.
Asthma prevalence and control characteristics by race/ethnicity–United States, 2002. MMWR Morb Mortal Wkly Rep. 2004 Feb 27. 53(7):145-8. [Medline].
Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, et al. National surveillance for asthma–United States, 1980-2004. MMWR Surveill Summ. 2007 Oct 19. 56(8):1-54. [Medline].
Arshad SH, Karmaus W, Raza A, Kurukulaaratchy RJ, Matthews SM, Holloway JW, et al. The effect of parental allergy on childhood allergic diseases depends on the sex of the child. J Allergy Clin Immunol. 2012 May 17. [Medline].
Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995 Jan 19. 332(3):133-8. [Medline].
Castro-Rodríguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000 Oct. 162(4 Pt 1):1403-6. [Medline].
Osterwell N. 50 Years On: Severe Childhood Asthma Persists in Middle Age. Medscape Medical News. Available at http://www.medscape.com/viewarticle/826597. Accessed: June 16, 2014.
Tai A, Tran H, Roberts M, Clarke N, Gibson AM, Vidmar S, et al. Outcomes of childhood asthma to the age of 50 years. J Allergy Clin Immunol. 2014 Jun. 133(6):1572-1578.e3. [Medline].
Coffman JM, Cabana MD, Yelin EH. Do school-based asthma education programs improve self-management and health outcomes?. Pediatrics. 2009 Aug. 124(2):729-42. [Medline]. [Full Text].
Wu AC, Tantisira K, Li L, Schuemann B, Weiss ST, Fuhlbrigge AL. Predictors of Symptoms are Different from Predictors of Severe Exacerbations from Asthma in Children. Chest. 2011 Feb 3. [Medline].
Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000 Jan. 161(1):309-29. [Medline].
Stern G, de Jongste J, van der Valk R, Baraldi E, Carraro S, Thamrin C, et al. Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. J Allergy Clin Immunol. 2011 Aug. 128(2):293-300. [Medline].
Robroeks CM, van Vliet D, Jöbsis Q, Braekers R, Rijkers GT, Wodzig WK, et al. Prediction of asthma exacerbations in children: results of a one-year prospective study. Clin Exp Allergy. 2012 May. 42(5):792-8. [Medline].
Wu AC, Tantisira K, Li L, Fuhlbrigge AL, Weiss ST, Litonjua A. Effect of vitamin D and inhaled corticosteroid treatment on lung function in children. Am J Respir Crit Care Med. 2012 Sep 15. 186(6):508-13. [Medline]. [Full Text].
Holbrook JT, Wise RA, Gold BD, et al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA. 2012 Jan 25. 307(4):373-81. [Medline].
Brozek JL, Kraft M, Krishnan JA, Cloutier MM, Lazarus SC, Li JT, et al. Long-Acting ß2-Agonist Step-off in Patients With Controlled Asthma: Systematic Review With Meta-analysis. Arch Intern Med. 2012 Aug 27. 1-11. [Medline].
Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006 Jan. 129(1):15-26. [Medline].
Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med. 2010 Apr. 123(4):322-8.e2. [Medline].
US Food and Drug Administration. FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABA). Human Department of Health and Human services. Feb 18, 2010. 1-4. [Full Text].
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. March 30, 2010. 362:975-85.
Pearlman DS, et al. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children (6-. Presented at the American College of Allergy, Asthma & Immunology 2016 Annual Scientific Meeting. San Francisco, CA</i>. 2016 Nov 13.
Rachelefsky G. Inhaled corticosteroids and asthma control in children: assessing impairment and risk. Pediatrics. 2009 Jan. 123(1):353-66. [Medline].
Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Feb 19. 377(9766):650-7. [Medline].
Farber HJ, Silveira EA, Vicere DR, et al. Oral Corticosteroid Prescribing for Children With Asthma in a Medicaid Managed Care Program. Pediatrics. 2017. 139(5):e20164146.
Kuehn BM. Asthma: Overuse of Oral Steroids Suggests Underuse of Inhalers. Medscape Medical News. Available at http://www.medscape.com/viewarticle/878503. April 12, 2017; Accessed: April 12, 2017.
Quon BS, Fitzgerald JM, Lemière C, Shahidi N, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. 2010 Dec 8. CD007524. [Medline].
Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000 Oct 12. 343(15):1064-9. [Medline].
Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med. 2000 Oct 12. 343(15):1054-63. [Medline].
Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011 Jan. 139(1):28-35. [Medline].
Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011 Mar 17. 364(11):1005-15. [Medline].
Omalizumab May Help Kids With Uncontrolled Allergic Asthma. Medscape. Apr 4 2013. [Full Text].
Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a one year real life survey. Eur Respir J. 2013 Mar 21. [Medline].
Cates CJ, Bestall J, Adams N. Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane Database Syst Rev. 2006 Jan 25. CD001491. [Medline].
Vuillermin PJ, Robertson CF, Carlin JB, Brennan SL, Biscan MI, South M. Parent initiated prednisolone for acute asthma in children of school age: randomised controlled crossover trial. BMJ. 2010 Mar 1. 340:c843. [Medline]. [Full Text].
Halterman JS, Szilagyi PG, Fisher SG, Fagnano M, Tremblay P, Conn KM, et al. Randomized controlled trial to improve care for urban children with asthma: results of the school-based asthma therapy trial. Arch Pediatr Adolesc Med. 2011 Mar. 165(3):262-8. [Medline].
Bhattacharjee R, Choi BH, Gozal D, Mokhlesi B. Association of adenotonsillectomy with asthma outcomes in children: a longitudinal database analysis. PLoS Med. 2014 Nov. 11(11):e1001753. [Medline]. [Full Text].
Harding A. Adenotonsillectomy for OSA improves asthma in kids. Reuters Health Information. November 06, 2014. [Full Text].
Postma DS, O’Byrne PM, Pedersen S. Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control. Chest. 2011 Feb. 139(2):311-8. [Medline].
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18. 380 (9842):651-9. [Medline].
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25. 371 (13):1198-207. [Medline]. [Full Text].
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25. 371 (13):1189-97. [Medline]. [Full Text].
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29. 388 (10056):2115-2127. [Medline].
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29. 388 (10056):2128-2141. [Medline].
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017 Jun 22. 376 (25):2448-2458. [Medline].
Henderson, D. Dexamethasone Tames Acute Asthma in Kids, With Less Vomiting. Medscape Medical News. Available at http://www.medscape.com/viewarticle/820375. Accessed: February 19, 2014.
Keeney GE, Gray MP, Morrison AK, Levas MN, Kessler EA, Hill GD, et al. Dexamethasone for Acute Asthma Exacerbations in Children: A Meta-analysis. Pediatrics. 2014 Feb 10. [Medline].
London S. Study Validates Asthma Symptom Tracker. Medscape Medical News. Nov 11 2013. [Full Text].
Nkoy FL, Stone BL, Fassl BA, et al. Longitudinal validation of a tool for asthma self-monitoring. Pediatrics. 2013 Nov 11. [Medline].
Scott M, Roberts G, Kurukulaaratchy RJ, Matthews S, Nove A, Arshad SH. Multifaceted allergen avoidance during infancy reduces asthma during childhood with the effect persisting until age 18 years. Thorax. 2012 Dec. 67(12):1046-51. [Medline].
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28. 378 (26):2486-2496. [Medline].
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018 Jun 28. 378 (26):2475-2485. [Medline].
Intermittent Asthma
Persistent Asthma: Daily Medication
Age
Step 1
Step 2
Step 3
Step 4
Step 5
Step 6
< 5 y
Rapid-acting beta2-agonist prn
Low-dose inhaled corticosteroid (ICS)
Medium-dose ICS
Medium-dose ICS plus either long-acting beta2-agonist (LABA) or montelukast
High-dose ICS plus either LABA or montelukast
High-dose ICS plus either LABA or montelukast; Oral systemic corticosteroid
Alternate regimen: cromolyn or montelukast
5-11 y
Rapid-acting beta2-agonist prn
Low-dose ICS
Either low-dose ICS plus either LABA, LTRA, or theophylline OR Medium-dose
Medium-dose ICS plus LABA
High-dose ICS plus LABA
High-dose ICS plus LABA plus oral systemic corticosteroid
Alternate regimen: cromolyn, leukotriene receptor antagonist (LTRA), or theophylline
Alternate regimen: medium-dose ICS plus either LTRA or theophylline
Alternate regimen: high-dose ICS plus either LABA or theophylline
Alternate regimen: high-dose ICS plus LRTA or theophylline plus systemic corticosteroid
12 y or older
Rapid-acting beta2-agonist as needed
Low-dose ICS
Low-dose ICS plus LABA OR Medium-dose ICS
Medium-dose ICS plus LABA
High-dose ICS plus LABA (and consider omalizumab for patients with allergies)
High-dose ICS plus either LABA plus oral corticosteroid (and consider omalizumab for patients with allergies)
Alternate regimen: cromolyn, LTRA, or theophylline
Alternate regimen: low-dose ICS plus either LTRA, theophylline, or zileuton
Alternate regimen: medium-dose ICS plus either LTRA, theophylline, or zileuton
Girish D Sharma, MD, FCCP, FAAP Professor of Pediatrics, Rush Medical College; Director, Section of Pediatric Pulmonology and Rush Cystic Fibrosis Center, Rush Children’s Hospital, Rush University Medical Center
Girish D Sharma, MD, FCCP, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, Royal College of Physicians of Ireland
Disclosure: Nothing to disclose.
Payel Gupta, MD Department of Allergy and Immunology, ENT Faculty Practice
Payel Gupta, MD is a member of the following medical societies: American College of Physicians
Disclosure: Nothing to disclose.
Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Nothing to disclose.
Charles Callahan, DO Professor, Chief, Department of Pediatrics and Pediatric Pulmonology, Tripler Army Medical Center
Charles Callahan, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American College of Osteopathic Pediatricians, American Thoracic Society, Association of Military Surgeons of the US, Christian Medical and Dental Associations
Disclosure: Nothing to disclose.
Kenan Haver, MD Assistant Professor of Pediatrics, Harvard Medical School; Associate Director of Asthma Program, Director of Flexible Bronchoscopy Program, Director of Pulmonary Division Asthma Program, Co-Director of Primary Ciliary Dyskinesia, Co-Leader of Empyema Standardized Clinical Assessment and Management Plans (SCAMP), Boston Children’s Hospital
Kenan Haver, MD is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society
Disclosure: Nothing to disclose.
Thomas Scanlin, MD Chief, Division of Pulmonary Medicine and Cystic Fibrosis Center, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School
Thomas Scanlin, MD is a member of the following medical societies: American Association for the Advancement of Science, Society for Pediatric Research, American Society for Biochemistry and Molecular Biology, American Thoracic Society, Society for Pediatric Research
Disclosure: Nothing to disclose.
Pediatric Asthma
Research & References of Pediatric Asthma|A&C Accounting And Tax Services
Source
0 Comments